New drug combo shows promise for Tough-to-Treat hairy cell leukemia
NCT ID NCT04324112
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of two oral drugs, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has either not responded to treatment or returned. About 28 adults will take the pills daily in 28-day cycles. The goal is to see if this combo can achieve a complete remission more often than existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- encorafenib and binimetinib
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with hairy cell leukemia that has stopped responding to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. Side effects from the two drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial